多学科方法改善了耐火性Helicobacter pylori感染的根除率和安全性
Na Dai1, Yu-Qin Zhao2, Wen-Juan Wu1
1Department of Gastroenterology, The First People's Hospital of Kunshan, Kunshan, China.
Clinical and translational gastroenterology
|December 18, 2024
概括
一个多学科团队 (MDT) 诊所在难以治疗的感染中显著提高了Helicobacter pylori根除率. 这种结合专家护理和个性化计划的方法带来了更高的成功率和更少的不良事件.
科学领域:
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
- 临床医学 临床医学
背景情况:
- 杆菌 (HP) 感染是一个全球性的健康问题,往往导致胃肠道疾病.
- 在HP中抗生素耐药性对有效的根除疗法构成重大挑战,导致耐药病例和不良事件增加.
研究的目的:
- 评估一种新的HP多学科团队 (MDT) 诊所在提高耐火HP感染的根除率方面的有效性.
- 在MDT框架内评估个性化治疗策略的安全性和影响.
主要方法:
- 一项比较研究包括153名耐火HP感染的患者,分为HP-MDT (102名患者) 和非HP-MDT (51名患者) 组.
- 惠普-MDT诊所提供量身定制的治疗计划,患者教育和随访,在某些特定情况下进行抗药性模式的基因测试.
主要成果:
- 惠普-MDT诊所出诊与明显更高的根除率有关 (80.39%与50.98%,P<0.001).
- 后勤回归证实MDT的出席是成功根除的独立预测因素 (OR:4.43,P<0.001).
- 基因测试显示对克拉里素 (90.91%) 和甲尼达 (100%) 的耐药性很高,但HP-MDT方法实现了92.31%的根除,副作用最小 (12.75%).
结论:
- 惠普-MDT临床模型有效提高了耐药HP感染患者的根除率和安全性.
- 医疗,制药和护理专业知识的整合,以及个性化护理和遗传洞察力,是克服抗生素耐药性和取得成功结果的关键.
相关概念视频
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
326
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
326
01:26Peptic Ulcer Disease IV: Management
72
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
72
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
88
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
88
01:23Gastritis III: Clinical Manifestations and Management
153
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
153
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
357
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
357
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356